CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

CureMatch Wins MetroConnect PitchFest $35,000 Grand Prize

CureMatch Wins MetroConnect PitchFest $35,000 Grand Prize
Awards

SAN DIEGO – June 8, 2018, World Trade Center San Diego and a live voting audience awarded $35K to local digital health oncology company CureMatch, as part of the MetroConnect Grand Prize PitchFest. Thank you to World Trade Center San Diego, and the grant awarded by JPMorgan Chase & Co. The real winners are those around the world benefiting from CureMatch’s continued innovation and technology in Precision Medicine developed specifically to help oncology professionals find the best cancer treatments.

►15 Million new cancer diagnosis each year GLOBALLY

►80% of them are getting the WRONG TREATMENT

►CureMatch finds ranks and matches FDA-approved CANCER TREATMENTS based on the DNA of a patient’s cancer


World Trade Center San Diego, through a grant provided by JPMorgan Chase & Co., and more than 100 business and community leaders awarded the MetroConnect Grand Prize to CureMatch, Inc, a local digital health company focused on personalized medicine and oncology.

“Three years in, the success of the MetroConnect program points to the importance of global trade and connectivity,” said Nikia Clarke, Ph.D., executive director of World Trade Center San Diego, the organization administering the grants. “From securing distribution partnerships in Japan to inking deals in key biotech hubs across the EU, the MetroConnect Grand Prize finalists are sharing their life-changing innovation with the world, helping strengthen San Diego’s economy and workforce.”

Managed by World Trade Center San Diego, an affiliate of the San Diego Regional EDC, and presented by JPMorgan Chase, the MetroConnect Grand Prize offers $35,000 to one of 15 companies to aid in their foreign market expansion. The finalists competing were CureMatch, FoxFury, Planck Aerosystems and Tioga Research.

The benefits of companies going global and engaging foreign markets are well-documented. According to the Brookings Institution, companies that are global pay their employees higher wages, are less likely to go out of business and spur more efficient development of technology and R&D.

In 2017 alone, San Diego exported $23.8 billion in goods and services from diverse industries including aircraft manufacturing to pharmaceutical R&D. Small- to medium-sized businesses produce 92 percent of those goods – undergirding the importance of programs like MetroConnect.

Now in its third year, MetroConnect has emerged as the region’s premier export assistance program. Run by World Trade Center San Diego, 15 companies are selected on an annual basis and equipped with a suite of programmatic and financial resources to help them in their plans to go global. Out of 50 applicants in 2017, just 15 San Diego companies were awarded the initial $10,000 MetroConnect grant, funded by JPMorgan Chase. Since the program’s inception in 2015, the cohort companies have produced an additional $15 million in export sales and 161 new jobs for the region, collectively.

A panel of judges consisting of business and community leaders reviewed the companies’ respective accomplishments and goals as a means of selecting the top four finalists to present at the Grand Prize event: CureMatch, FoxFury, Planck Aerosystems and Tioga Research.

“CureMatch is thrilled to win the Pitchfest, with special thanks to World Trade Center San Diego and JPMorgan Chase,” said Stephane Richard, Ph.D., president and CEO of CureMatch.

“Cancer has no boundaries, so while CureMatch was born in San Diego, we believe that every one of the more than 15 million people diagnosed with cancer this year deserves the best treatment. This grand prize will help CureMatch save more lives around the world.”

“JPMorgan Chase is committed to helping local businesses connect to the global marketplace,” said Tim West, region manager of JPMorgan Chase’s Middle Market Commercial Banking practice in San Diego. “We congratulate the finalists for their efforts to grow their businesses internationally while creating jobs and boosting our local economy.”

For more information about MetroConnect, visit MetroConnectsd.org.

About World Trade Center San Diego
World Trade Center San Diego operates as an affiliate of San Diego Regional Economic Development Corporation. WTC San Diego works to further San Diego’s global competitiveness by building an export pipeline, attracting and retaining foreign investment and increasing San Diego’s global profile abroad. sandiegobusiness.org/wtcsd

About CureMatch®
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations in cost-effective PreciGENE reports. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com

CureMatch Media Contact:
Name: Larissa Anderson
Company: CureMatch
Phone: (858) 859-2873
Email: press@curematch.com

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data